Insights & News

DeeMED publishes practical insights on Thai FDA regulations, medical cannabis compliance, cold chain logistics, and international trade. Written for operators, buyers, and investors navigating regulated markets in Thailand and beyond.

No articles match your search. Try different keywords.

Medical Cannabis

Thailand's Cannabis and Hemp Act: Still Stalled, Still Consequential for Export Operators

June 17, 2026 | Medical Cannabis

By Jerrod Lottinger | Founder, DeeMED Consulting

Thailand's Cannabis and Hemp Act cleared only its first parliamentary reading and remains stalled, leaving three separate ministerial instruments governing the industry with no unified licensing authority. A December 31, 2026 license cliff for extract operators adds urgency while legislators remain gridlocked. Here is why the legislative vacuum matters strategically and what operators should be doing while waiting.

Read Article →

Germany's MedCanG Amendment: What Proposed Prescription Restrictions Mean for Medical Cannabis Exporters

June 16, 2026 | Medical Cannabis

By Jerrod Lottinger | Founder, DeeMED Consulting

Germany's CDU/CSU-led coalition drafted a MedCanG amendment in late 2025 that would restrict telemedicine prescriptions, ban mail-order pharmacy dispensing, and require in-person consultations for new cannabis patients. The bill passed cabinet in October 2025 and had its first Bundestag reading in December, but SPD opposition has stalled it with no passage timeline confirmed. Here is what exporters targeting Germany need to understand.

Read Article →

Germany's Medical Cannabis Market in 2025-2026: What the Import Data Reveals About Supply Competition

June 15, 2026 | Medical Cannabis

By Jerrod Lottinger | Founder, DeeMED Consulting

Germany imported 201,094 kilograms of medical cannabis in full-year 2025, nearly tripling from 72,706 kg in 2024, with Canada supplying 53% of volume and Portugal operating as a re-export processing hub rather than a true origin market. Q1 2026 shows 50,539 kg already cleared. For Thai exporters, this data reveals exactly where the market is and what it requires to enter it.

Read Article →

Thailand's April 2026 Cannabis Regulations: What Exporters Must Know Now

June 1, 2026 | Medical Cannabis

By Jerrod Lottinger | Founder, DeeMED Consulting

Two ministerial regulations took effect in April 2026 that fundamentally reshape how Thailand licenses cannabis extract production and export. Foreign-owned entities are excluded from holding extract production licenses. Existing licenses expire December 31, 2026 and require full re-qualification. Here is what international buyers, investors, and Thai operators need to act on now.

Read Article →

Thailand's April 30 Cannabis Licence Crackdown Meets Europe's Accelerating Demand: What Exporters Must Understand Now

May 24, 2026 | Medical Cannabis

By Jerrod Lottinger | Founder, DeeMED Consulting

Thailand's April 30 ministerial regulation restricts cannabis licences to registered medical facilities, pharmacies, and herbal shops only. Around 12,000 licences face renewal in 2026-2027. At exactly the same moment, Europe's medical cannabis market is accelerating with Germany, UK, Portugal, and Italy all expanding fast. Here is what Thai exporters and their international buyers need to understand right now.

Read Article →

Thailand's Medical Cannabis Export Market in 2026: What the Data Actually Shows

May 20, 2026 | Medical Cannabis

By Jerrod Lottinger | Founder, DeeMED Consulting

As of February 2026, only 217 out of over 11,800 legacy-licensed operators hold DTAM GACP certification. Here is what the data actually shows about Thailand's medical cannabis export market in 2026, beyond the headlines.

Read Article →

Thailand's June 2025 Cannabis Notification — What It Means for Exporters and Cultivators

May 12, 2026 | Medical Cannabis

By Jerrod Lottinger | Founder, DeeMED Consulting

Thailand's Ministry of Public Health issued its Notification on Controlled Herbs (Cannabis) in June 2025, returning the market to a strictly medical model. For cultivators and exporters, DTAM-certified GACP is now legally mandatory, and non-compliant shipments face seizure at customs. Here is what you need to know and how to prepare.

Read Article →

Thai GACP vs EU-GACP vs CUMCS — Which Standard Does Your Buyer Actually Require?

April 21, 2026 | Medical Cannabis

By Jerrod Lottinger | Founder, DeeMED Consulting

Not all GACP certifications are equal in the eyes of international buyers. CUMCS from Control Union is formally recognized by Israel's IMCA Ministry of Health for all cannabis imports, and by EU and Australian buyers as credible independent compliance proof. Understanding the difference could determine whether your shipment gets accepted or rejected.

Read Article →

Thailand as Asia's Medical Cannabis Hub: Opportunity, Competition, and What It Takes to Win

April 14, 2026 | Medical Cannabis

By Jerrod Lottinger | Founder, DeeMED Consulting

Thailand has real competitive advantages in medical cannabis, but Canada, Portugal, and Germany remain dominant exporters. This article examines where Thailand's genuine advantage lies and what it takes to win internationally.

Read Article →

Exporting Medical Cannabis from Thailand to Australia: A Practical Compliance Guide

March 30, 2026 | Medical Cannabis

By Jerrod Lottinger | Founder, DeeMED Consulting

Australia is one of the most commercially significant and technically demanding export markets for Thai medical cannabis. TGA import requirements, ODC permit sequencing, documentation, cold chain logistics, and common failure points explained.

Read Article →

EU-GMP Certification for Thai Cannabis Manufacturers — Timeline, Process, and What to Expect

February 16, 2026 | Medical Cannabis

By Jerrod Lottinger | Founder, DeeMED Consulting

EU-GMP Part I certification is the most important compliance milestone for Thai cannabis manufacturers targeting European markets. This guide covers every phase from gap assessment to certificate issuance, referenced directly against EudraLex Volume 4.

Read Article →

Why Anutin Charnvirakul Becoming Prime Minister Matters for Thailand's Cannabis Industry

January 12, 2026 | Medical Cannabis

By Jerrod Lottinger | Founder, DeeMED Consulting

Anutin Charnvirakul's election as Prime Minister on September 5, 2025, consolidates executive authority in the hands of the figure most responsible for Thailand's cannabis liberalization. Here is what it changes for the industry, and what it does not.

Read Article →

Navigating Global Cannabis Compliance: How Export Deals Work, Timelines, and the Future of Thai Cannabis (Part II)

December 5, 2025 | Medical Cannabis

By Jerrod Lottinger | Founder, DeeMED Consulting

Part II: How deals actually get done, from compliance to first shipment. Realistic 6 to 12 month timelines, regulatory approvals, logistics sequencing, and Thailand's long-term outlook as a global supplier. Originally published on LinkedIn.

Read Article →

Navigating Global Cannabis Compliance: Thai GACP, EU-GACP, CUMCS, Thai GMP, and EU-GMP (Part I)

December 3, 2025 | Medical Cannabis

By Jerrod Lottinger | Founder, DeeMED Consulting

Part I: The standards explained. GACP, GMP, GDP, and what Thai cultivators and manufacturers need to understand before targeting EU and Australian export markets. Originally published on LinkedIn.

Read Article →

Thailand Medical Cannabis Export in 2025: What Is Actually Realistic?

December 2, 2025 | Medical Cannabis

By Jerrod Lottinger | Founder, DeeMED Consulting

A grounded view for EU and UK buyers evaluating Thailand as a medical cannabis sourcing country in 2025. What is legally possible, what the operational reality looks like, and how to approach due diligence properly. Originally published on LinkedIn.

Read Article →

Thai FDA & Regulatory

TFDA Labeling Deadline June 20, 2026: Final Compliance Checklist for Foreign Manufacturers

June 1, 2026 | Thai FDA

By Jerrod Lottinger | Founder, DeeMED Consulting

Thailand's new medical device labeling regulation B.E. 2568 takes effect in 19 days. The two-year transition period protects existing inventory but not new registrations, renewals, or variation applications filed after June 20. A practical checklist covering mandatory label content, language classification by device type, the shortened 120-day import labeling window, and what to confirm about pending submissions before the deadline passes.

Read Article →

The MDA-Thai FDA Reliance Programme Is Now Fully Live: What Foreign Manufacturers Need to Do with It

May 24, 2026 | Thai FDA

By Chalita (BB) Toskaew | Co-Founder, DeeMED Consulting

The MDA-Thai FDA Medical Device Regulatory Reliance Programme moved to full implementation on May 1, 2026. Class B, C, and D devices already registered with Malaysia's MDA can now bypass full expert evaluation at Thai FDA. Here is exactly how the programme works, who qualifies, what the documentation requirements are, and how to use it strategically for ASEAN market entry.

Read Article →

Stem Cells and Advanced Cellular Therapies in Thailand — Regulatory Pathways, Real Challenges, and What Manufacturers Need to Know

May 8, 2026 | Thai FDA

By Jerrod Lottinger | Founder, DeeMED Consulting

The Thai FDA added an ATMP Conditional Approval route in October 2024 that permits early marketing of cell, gene, and tissue-based therapies. The pathway remains one of the most demanding in Southeast Asia. GMP certification requirements and limited reviewer capacity create real barriers that require early engagement.

Read Article →

New TFDA Labeling Requirements Effective June 2026 — What Foreign Manufacturers Need to Do Now

April 15, 2026 | Thai FDA

By Jerrod Lottinger | Founder, DeeMED Consulting

Thailand's Ministry of Public Health finalized new medical device labeling and IFU requirements in December 2025, effective June 20, 2026. Bilingual Thai-English labeling is now acceptable, but specific requirements have been tightened. Foreign manufacturers must act now to avoid market disruption.

Read Article →

Revised Manufacturing License Requirements Effective May 2026 — What You Need to Know

April 1, 2026 | Thai FDA

By Jerrod Lottinger | Founder, DeeMED Consulting

Thailand introduced revised manufacturing license requirements effective May 2026 alongside modernized application processes. Foreign manufacturers and their local authorized representatives need to understand how these changes affect establishment licensing, renewal timelines, and import authorization.

Read Article →

Class 1 Auto-Approval — What the January 2025 TFDA Change Means for Your Market Entry

March 13, 2026 | Thai FDA

By Jerrod Lottinger | Founder, DeeMED Consulting

Since January 2025, qualifying Class 1 medical devices on the TFDA Positive List receive automatic registration numbers upon submission, compressing timelines from months to days. Here is how to determine if your device qualifies.

Read Article →

The TFDA Positive List Explained — Which Class 1 Devices Qualify for Auto-Approval

March 10, 2026 | Thai FDA

By Jerrod Lottinger | Founder, DeeMED Consulting

The Positive List is a catalogue of device categories identified by GMDN codes that qualify for auto-approval. Understanding which devices qualify, and how to structure your submission to take full advantage, can eliminate months from your market entry timeline.

Read Article →

Dermal Fillers and Borderline Devices in Thailand — Navigating the Drug-Device Divide

February 27, 2026 | Thai FDA

By Jerrod Lottinger | Founder, DeeMED Consulting

In borderline cases such as dermal fillers, the TFDA may require additional documents and expert committee review. Hyaluronic acid fillers are generally Class 3 or 4 medical devices in Thailand. Misclassifying as a cosmetic can result in mandatory withdrawal and criminal liability.

Read Article →

UDI Requirements Coming for Class 2-4 Medical Devices — Two-Year Transition Period Explained

February 6, 2026 | Thai FDA

By Jerrod Lottinger | Founder, DeeMED Consulting

In March 2025 the Thai FDA released draft guidance introducing Unique Device Identifier requirements for Class 2, 3, and 4 medical devices. A two-year transition period applies for devices already compliant with 2020 labeling rules. Foreign manufacturers need to begin planning now.

Read Article →

Thailand-Malaysia Regulatory Reliance Pilot — What the ASEAN Cascade Could Mean for You

January 19, 2026 | Thai FDA

By Jerrod Lottinger | Founder, DeeMED Consulting

Thailand and Malaysia have launched a pilot program for regulatory reliance where devices approved by Malaysia's MDA can receive expedited review in Thailand. Combined with existing reliance pathways from EU MDR and Singapore HSA, this could create a powerful multi-market ASEAN registration cascade.

Read Article →

Software as a Medical Device in Thailand — New Classification Guidelines Explained

December 31, 2025 | Thai FDA

By Jerrod Lottinger | Founder, DeeMED Consulting

The TFDA released new registration guidelines for Software as a Medical Device in 2025, aligning with the IMDRF framework and introducing formal cybersecurity documentation requirements. For companies developing AI-powered diagnostics or clinical decision support tools, understanding these classifications is essential.

Read Article →

Logistics & Cold Chain

Two Chokepoints at Once: How the Hormuz Closure Compounds Thailand's Pharmaceutical Cold Chain Risk

June 18, 2026 | Logistics

By Jerrod Lottinger | Founder, DeeMED Consulting

When US-Israeli airstrikes triggered Strait of Hormuz closure on March 2-4, 2026, Thai pharmaceutical exporters faced a compounding crisis: Hormuz shut while the Red Sea remains 60% below its 2023 Suez Canal transit volumes. The dual chokepoint adds 10-14 transit days via Cape of Good Hope, triggers GDP deviation reporting requirements, and closes Iran airspace for air freight. Here is what the compounding effect means for supply chain documentation and routing strategy.

Read Article →

Cathay Cargo's Biopharma Cold Chain Push: What It Means for Thai Pharmaceutical Exporters

June 1, 2026 | Logistics

By Jerrod Lottinger | Founder, DeeMED Consulting

Cathay Cargo's May 19 expansion of its Cathay Pharma IATA CEIV Pharma-certified network through Hong Kong International Airport reshapes routing options for Thai pharmaceutical exporters. Here is how to evaluate whether HKG transit improves your shipment profile, and why medical cannabis exports are specifically excluded regardless of documentation.

Read Article →

The Middle East Conflict Is Not a Temporary Disruption Anymore: What Thai Pharmaceutical Exporters Must Plan For Now

May 24, 2026 | Logistics

By Jerrod Lottinger | Founder, DeeMED Consulting

Three months after the February 28 strikes on Iran, the Strait of Hormuz remains effectively shut and the GCCA's May 20 situation report confirms mine-clearing will not restore commercial viability before Q4 2026. Dubai and Doha air cargo remain operationally fragile. For Thai medical cannabis and pharmaceutical exporters, this is now the logistics baseline for the rest of 2026, not a temporary exception.

Read Article →

Pharma Cold-Chain Telemetry in 2026: From Reactive Logs to Predictive Control

May 19, 2026 | Logistics

By Chalita (BB) Toskaew | Co-Founder, DeeMED Consulting

Real-time telemetry, once a premium add-on, is hardening into a regulatory baseline in 2026. The WHO's 2025 vaccine guidelines and IQVIA's USD 35 billion annual loss figure are reframing how pharmaceutical operators think about temperature assurance.

Read Article →

Thailand's Pharmaceutical Cold Chain Market Is Growing Fast — What It Means for Regulated Importers

April 27, 2026 | Logistics

By Jerrod Lottinger | Founder, DeeMED Consulting

Thailand's cold chain logistics market is valued at USD 2.4 billion in 2026 (Mordor Intelligence) with pharmaceuticals as the fastest-growing segment. For international companies importing regulated products into Thailand, choosing the right GDP-certified partner remains critical.

Read Article →

INCB Export Authorization and UN Single Convention Compliance for Medical Cannabis Shipments

March 17, 2026 | Logistics

By Jerrod Lottinger | Founder, DeeMED Consulting

Every international medical cannabis shipment must navigate the UN Single Convention on Narcotic Drugs, INCB authorization procedures, and destination country controlled substance regulations simultaneously. Getting any one of these wrong can result in shipment seizure or criminal liability.

Read Article →

GDP Compliance for Medical Cannabis Shipments — What Documentation You Actually Need

March 13, 2026 | Logistics

By Jerrod Lottinger | Founder, DeeMED Consulting

GDP-compliant medical cannabis exports require a complete documentation package that satisfies customs authorities, destination country importers, and pharmaceutical-grade buyer audits simultaneously. This article outlines every document required before, during, and after shipment.

Read Article →

Real-Time Visibility vs Passive Logging — Choosing the Right Data Logger for Your Shipment

February 25, 2026 | Logistics

By Jerrod Lottinger | Founder, DeeMED Consulting

Not all temperature monitoring approaches deliver the same level of compliance assurance. For GDP-audited pharmaceutical and medical cannabis cargo, the difference between passive and real-time monitoring has direct implications for your compliance documentation and ability to respond to excursions.

Read Article →

Why Single-Use Data Loggers Are Non-Negotiable for High-Value Pharmaceutical Exports

February 4, 2026 | Logistics

By Jerrod Lottinger | Founder, DeeMED Consulting

For temperature-sensitive and high-value pharmaceutical cargo, reusable data loggers introduce chain-of-custody and calibration risks that single-use devices eliminate entirely. A single-use GDP-compliant logger provides an unbroken, tamper-evident environmental record from origin to destination.

Read Article →